Lazard Asset Management
ALLO icon

Lazard Asset Management’s Allogene Therapeutics ALLO Stock Holding History

Lazard Asset Management’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-96
Closed – – 2292
2024
Q4 		$0 Hold
96
– – ﹤0.01% 2263
2024
Q3 		$0 Sell
96
-160
-63% -$427 ﹤0.01% 2251
2024
Q2 		$0 Sell
256
-3,605
-93% -$10.6K ﹤0.01% 2217
2024
Q1 		$16K Sell
3,861
-2,137
-36% -$8.92K ﹤0.01% 1855
2023
Q4 		$18K Buy
5,998
+249
+4% +$706 ﹤0.01% 2062
2023
Q3 		$17K Buy
5,749
+250
+5% +$1.1K ﹤0.01% 2113
2023
Q2 		$26K Buy
5,499
+1,783
+48% +$9.64K ﹤0.01% 2047
2023
Q1 		$18K Buy
3,716
+806
+28% +$5.17K ﹤0.01% 2064
2022
Q4 		$17K Buy
+2,910
New +$26.9K ﹤0.01% 2147
2021
Q3 		– Sell
-1,848
Closed -$48K – 2141
2021
Q2 		$48K Buy
+1,848
New +$52.7K ﹤0.01% 1610

Other funds holding ALLO

P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Lazard Asset Management's ALLO Position: Q1 2025 in Review

Lazard Asset Management sold out of Allogene Therapeutics (ALLO) in Q1 2025, closing a stake of 96 shares.

Lazard Asset Management first reported a position in ALLO in Q2 2021 and held it in 10 quarters. The position peaked at $48K in Q2 2021. 170 funds tracked by Wall St. Rank hold ALLO as of Q1 2025.

  • Lazard Asset Management reported no remaining Allogene Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Lazard Asset Management sold 96 Allogene Therapeutics shares in Q1 2025.
  • Lazard Asset Management first reported a position in Allogene Therapeutics in Q2 2021 and held it in 10 quarters.
  • Lazard Asset Management's Allogene Therapeutics position peaked at $48K in Q2 2021.
  • 170 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q1 2025.

Based on Lazard Asset Management's 13F filing for Q1 2025, filed 15 May 2025.